This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. MBX, RVNC, CKPT, AVTE, TSVT, SLRN, CYBN, BIOA, NLTX, and PROCShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Procaps Group (PROC). Millendo Therapeutics vs. Its Competitors MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics 2seventy bio Acelyrin Cybin BioAge Labs Neoleukin Therapeutics Procaps Group Millendo Therapeutics (NASDAQ:MLND) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Is MLND or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Millendo TherapeuticsN/A -91.03% -72.44% MBX Biosciences N/A N/A N/A Do analysts recommend MLND or MBX? MBX Biosciences has a consensus target price of $37.50, indicating a potential upside of 202.49%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Millendo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Millendo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, MLND or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMillendo TherapeuticsN/AN/A-$36.41MN/AN/AMBX BiosciencesN/AN/AN/AN/AN/A Does the media favor MLND or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Millendo Therapeutics. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Millendo Therapeutics. MBX Biosciences' average media sentiment score of 1.91 beat Millendo Therapeutics' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Millendo Therapeutics Neutral MBX Biosciences Very Positive SummaryMBX Biosciences beats Millendo Therapeutics on 7 of the 7 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.20M$800.81M$5.57B$9.02BDividend YieldN/A4.84%5.25%4.03%P/E RatioN/A1.3027.2120.15Price / SalesN/A227.16416.26185.35Price / CashN/A23.4437.0657.97Price / Book4.226.158.085.60Net Income-$36.41M-$27.58M$3.16B$248.50M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$7.52+1.1%N/A+246.0%$143.20MN/A0.0012MBXMBX Biosciences2.5509 of 5 stars$11.61+1.8%$37.50+223.0%N/A$388.05MN/A0.0036RVNCRevance Therapeutics2.7757 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.5333 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-82.2%$289.56MN/A-3.3420Gap UpHigh Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CYBNCybin2.9265 of 5 stars$9.00+7.3%$86.00+855.6%N/A$207.22MN/A-2.0550Analyst ForecastHigh Trading VolumeBIOABioAge LabsN/A$4.13flatN/AN/A$148.06MN/A0.00N/ANews CoverageNLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-44.9%$140.50MN/A-4.8190High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading Volume Related Companies and Tools Related Companies MBX Alternatives RVNC Alternatives CKPT Alternatives AVTE Alternatives TSVT Alternatives SLRN Alternatives CYBN Alternatives BIOA Alternatives NLTX Alternatives PROC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
